{"entity":{"id":"proteasome-inhibitor-payloads","kind":"term","name":"Proteasome inhibitor payloads","aka":["carfilzomib conjugate payload","lysosomal payload inactivation"],"tldr":"Blocking a cell's protein-disposal machinery is one proposed payload strategy. A study of antibody-linked carfilzomib shows why a drug that works on its own can lose activity after delivery.","summary":"Carfilzomib was attached to antibodies against CD22 or HER2, but the resulting conjugates lost their cell-killing potency. The primary study found that lysosomal enzymes could release carfilzomib and then inactivate it. This is negative evidence for those constructs, not evidence that proteasome inhibition can never work as a payload. Intracellular chemical stability must be tested alongside release and target potency.","asOf":"2026-11-08","links":[{"label":"Carfilzomib conjugates and lysosomal inactivation (2019)","url":"https://doi.org/10.1124/dmd.119.086595"}],"tags":["failure"],"related":["proteasome-inhibitor"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["carfilzomib"],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/proteasome-inhibitor-payloads/","neighbours":{"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"proteasome-inhibitor","kind":"term","name":"Proteasome inhibitor (bortezomib, carfilzomib, ixazomib)","route":"/terms/proteasome-inhibitor/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/"}]}}